Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Express Scripts
Colorcon
Johnson and Johnson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Litigation Details for ASTRAZENECA AB v. IVAX CORPORATION (D.N.J. 2008)

See Plans and Pricing

« Back to Dashboard

ASTRAZENECA AB v. IVAX CORPORATION (D.N.J. 2008)

Docket   Start Trial Date Filed 2008-10-09
Court District Court, D. New Jersey Date Terminated 2009-03-25
Cause 35:271 Patent Infringement Assigned To Joel A. Pisano
Jury Demand None Referred To Magistrate Judge Tonianne J. B
Parties AKTIEBOLAGET HASSLE; ASTRAZENECA AB; ASTRAZENECA LP; CIPLA, LTD; IVAX CORPORATION; IVAX PHARMACEUTICALS NV, INC; IVAX PHARMACEUTICALS, INC.; KBI INC.; KBI-E INC.; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patents 4,255,431; 4,738,974; 4,786,505; 5,690,960; 5,817,338; 5,900,424
Attorneys ANDREW T. BERRY; JONATHAN M.H. SHORT; MARK H. ANANIA; MAYRA VELEZ TARANTINO; MICHAEL E. PATUNAS
Firms McCarter & English, LLP; Patunas Tarantino LLC
Link to Docket External link to docket
Small Molecule Drugs cited in ASTRAZENECA AB v. IVAX CORPORATION
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for ASTRAZENECA AB v. IVAX CORPORATION (D.N.J. 2008)

Date Filed Document No. Description Snippet Link To Document
2008-10-09 1 Letters Patent No. 2,290,963. U.S. PATENT DOCUMENTS 4,255,431 A … an action for patent infringement and a declaratory judgment arising under the Patent and Food and Drug…toward infringement of United States Patent No. 7,411,070 (“the ’070 patent”) by, inter alia, submitting an…expiration of the ’070 patent. CLAIM FOR RELIEF: ’070 PATENT …been and is still the owner of the ’070 patent. The ’070 patent will expire on May 25, 2018 and pediatric External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Moodys
Johnson and Johnson
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.